Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GK Activator 2 + glyburide
- Development stage
- Unknown
- Lead developer
- Hua Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GK Activator 2 + glyburide is an experimental **combination therapy** used in clinical studies for **type 2 diabetes mellitus**. GK Activator 2 is a small molecule *glucokinase activator*, which increases glucokinase activity in pancreatic beta cells and the liver, leading to enhanced glucose-stimulated insulin secretion and increased hepatic glucose utilization. Glyburide is a well-established sulfonylurea that acts by closing ATP-sensitive potassium channels (sulfonylurea receptor 1) on pancreatic beta cells, directly stimulating insulin release. The combination is investigated for its potential synergistic glucose-lowering effects, with clinical studies showing greater reductions in fasting plasma glucose when both drugs are administered together compared to either drug alone. The main safety concern is hypoglycemia, which is increased when both agents are combined. GK Activator 2 is not yet approved or marketed; glyburide is approved for the treatment of type 2 diabetes.
- Other names
- GK Activator 2 + glyburideglucokinase activator 2 + glyburide
02
Targets
GCK (Glucokinase)KATP channel (ATP-sensitive potassium channel)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on GK Activator 2 + glyburide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GK Activator 2 + glyburide.